0001178913-26-002458
SEC filingEntera Bio reported wider Q1 2026 operating losses of $3.5M versus $2.6M prior year as clinical-stage biotech advances product candidates into later development stages with inherently higher costs, while revenue ceased after prior-period research services ended.
Entera Bio Ltd., a clinical-stage biopharmaceutical company leveraging its N-Tab peptide tablet technology, reported results for the quarter ended March 31, 2026, reflecting the financial realities of advancing oral peptide delivery programs. Revenue fell to $0 from $42,000 in the prior-year quarter, as research services that generated the modest prior revenue ended. This aligns with the company's pre-commercial status, where gross profit remained at zero as expected.
Operating income deteriorated to -$3,539,000 from -$2,563,000 year-over-year, a 38.1% widening of losses. This reflects the structural economics of clinical development: product candidates in later stages generally incur higher costs than earlier phases, primarily due to the increased size and duration of later-stage clinical trials. Research and development expenses consist of costs for the N-Tab platform and product candidates, and management notes these will increase significantly in future periods as clinical programs progress and additional preclinical work begins. Net income followed suit at -$3,505,000 versus -$2,567,000, a 36.5% deeper loss, with diluted EPS showing a modest $0.07 loss versus $0.06 prior year—a 16.7% relative improvement.
Cash flow from operations consumed -$3,090,000, up from -$1,404,000 last year, underscoring persistent negative cash flows since inception amid significant operational losses. With no capital expenditures, free cash flow matched operating cash use at -$3.1M. These dynamics highlight liquidity pressures: to fund further operations, additional capital will be required, consistent with the company's history of negative cash generation.
Overall, these results emphasize Entera Bio's transition toward costlier late-stage development while maintaining focus on overcoming oral delivery challenges like gastrointestinal enzymatic degradation and poor absorption. Investors should note the ongoing need for capital raises to sustain runway, as the company invests in its pipeline without near-term revenue offsets.